WO1990004407A1 - Cpf peptide compositions and uses - Google Patents
Cpf peptide compositions and uses Download PDFInfo
- Publication number
- WO1990004407A1 WO1990004407A1 PCT/US1989/004625 US8904625W WO9004407A1 WO 1990004407 A1 WO1990004407 A1 WO 1990004407A1 US 8904625 W US8904625 W US 8904625W WO 9004407 A1 WO9004407 A1 WO 9004407A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- amino acid
- basic
- cpf
- amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention as related to the use of certain peptides and to compositions containing such peptides. More particularly, the present invention is directed to pharmaceutical uses and compositions of certain peptides known as CPF peptides and
- composition comprised of CPF peptides and/or biologically active analogues or derivatives thereof and a pharmaceutical carrier.
- a CPF peptide and/or biologically active analogue or derivative thereof is administered to inhibit growth of a target cell or cells.
- analogue and/or derivative encompasses peptides having more or less amino acids than the CPF peptides and one or more changes in the amino acids of the CPF peptide.
- CPF peptides derivatives thereof are herein sometimes referred to collectively as CPF peptides.
- the CPF peptide is preferably one which includes the following basic peptide structure x:
- R 1 is a hydroph ⁇ bic amino acid
- R 2 is a hydrophobic amino acid or a basic hydrophilic amino acid
- R 3 is a basic hydrophilic amino acid
- R 4 is a hydr ⁇ phobic or neutral hydrophilic amino acid
- R 5 is a basic or neutral hydrophilic amino acid.
- hydrophobic amino acids are Ala, Cys, Phe, Gly, lie, Leu, Met, Val, Trp, and Tyr.
- the neutral hydrophilic amino acids are Asn, Gin, Ser, and Thr.
- the basic hydrophilic amino acids are Lys, Arg, and His.
- the CPF peptide may include only the hereinabove noted amino acids or may include additional amino acids at the amino and/or carboxyl end or both the amino and carboxyl end. In general, the peptide does not include more than 40 amino acids.
- the CPF peptides including the above basic structure preferably have from 1 to 4 additional amino acids at the amino end.
- R 1 , R 2 and R 5 are as previously defined.
- the carboxyl end of the basic peptide structure may also have additional amino acids which may range from 1 to 13 additional amino acids.
- the basic structure may have from 1 to 7 additional amino acids at the carboxyl end, which may be represented as follows:
- X is the hereinabove defined basic peptide structure and Z is
- R 1 -R 1 -R 4 -R 4 -R 6 -Gln-Gln wherein R 1 and R 4 are as previously defined, and R 6 is proline or a hydrophobic amino acid.
- Preferred peptides may be represented by the following structural formula
- CPF like peptides used in the present invention, there may be mentioned peptides represented by the following (single letter amino acid code):
- the numbered amino acids may be employed as described in any combination to provide either a basic CPF peptide structure or an analogue or
- an ion channel forming peptide or ionophore is one which increases the permeability for ions across a natural or synthetic lipid membrane.
- Christensen et al. PNAS Vol. 85 P. 5072-76 (July 1988) describes methodology which indicates whether or not a peptide has ion channel properties and is therefore an ionophore.
- a used herein an ion channel- forming peptide is a peptide which has ion channel-forming properties as determined by the method of
- the CPF peptides and/or analgoues or derivatives thereof are generally water soluble to a concentration of at least 20 mg/ml at neutral pH in water.
- such peptides are non-hemolytic; i.e., they will not rupture blood cells at effective concentrations.
- the structure of such peptide provides for flexibility of the peptide molecule. When the peptide is placed in water, it does not assume an amphiphilic structure. When the peptide encounters an oily surface or membrane, the peptide chain folds upon itself into a rod-like structure.
- the CPF peptides and/or analogues or derivatives thereof may be administered to a host; for example a human or non-human animal, in an amount effective to inhibit growth of a target cell.
- a host for example a human or non-human animal
- the CPF peptides and/or analogues or derivatives thereof may be used as antimicrobial agents
- anti-viral agents antibiotics, anti-tumor agents, spermicides, as well as exhibiting other bioactive functions.
- antimicrobial means that the polypeptides of in the present invention inhibit, prevent, or destroy the growth or
- microbes such as bacteria, fungi, viruses, or the like.
- antibiotic means that the polypeptides employed in the present invention produce effects adverse to the normal biological functions of the cell, tissue, or organism including death or destruction and prevention of the growth or proliferation of the biological system when contacted with the polypeptides.
- spermicidal means that the polypeptides employed in the present invention, inhibit, prevent, or destroy the motility of sperm.
- antiviral means that the polypeptides employed in the present invention inhibit, prevent, or destroy the growth or
- anti-tumor means that the polypeptide inhibits the growth of or destroys tumors.
- the polypeptides of the present invention have a broad range of potent antibiotic activity against a plurality of microorganisms including gram-positive and gram-negative bacteria, fungi, protozoa, and the like.
- the polypeptides of the present invention allow a method for treating or controlling microbial infection caused by organisms which are sensitive to the polypeptides. Such treatment may comprise administering to a host organism or tissue
- the polypeptides may also be used as preservatives or sterilants of materials susceptible to microbial contamination.
- the CPF peptide and/or derivatives or analogues thereof may be administered in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
- a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
- Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule, or the like.
- the polypeptide compositions may also be used in combination with adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in controlling infection caused by harmful
- microorganisms including protozoa viruses, and the like.
- the pe ⁇ tide(s) of the present invention may be administered to a host; in particular an animal, in an effective antibiotic and/or anti-tumor and/or anti-viral and/or anti-microbial and/or an
- the peptides when used in topical compositions, are generally present in an amount of at least 0.1%, by weight. In most cases, it is not necessary to employ the peptide in an amount greater than 1.0%, by weight.
- the active peptide is present in an amount to achieve a serum level of the peptide of at least about 5 ug/ml.
- the serum level of peptide need not exceed 500 ug/ml.
- a preferred serum level is about 100 ug/ml.
- Such serum levels may be achieved by incorporating the peptide in a composition to be administered systemically at a dose of from 1 to about 10 mg/kg.
- the ⁇ eptide(s) need not be administered at a dose exceeding 100 mg/kg.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
CPF peptides and/or analogues or derivatives are used as a pharmaceutical. Such peptides have antibiotic and/or anti-viral and/or anti-tumor and/or anti-spermicidal activity.
Description
CPF PEPTIDE COMPOSITIONS AND USES
The present invention as related to the use of certain peptides and to compositions containing such peptides. More particularly, the present invention is directed to pharmaceutical uses and compositions of certain peptides known as CPF peptides and
analogues and derivatives thereof.
Some of the CPF peptides which are used in the present invention have been described in the
literature and comprise the following sequences:
(1) GFGSFLGLALKAALKIGANALGGAPQQ
(2) GLASFLGKALKAGLKIGAHLLGGAPQQ
(3) GLASLLGKALKAGLKIGTHFLGGAPQQ
(4) GLASLLGKALKATLKIGTHFLGGAPQQ
(5) GFASFLGKALKAALKIGANMLGGTPQQ
(6) GFGSFLGKALKAALKIGANALGGAPQQ
(7) GFGSFLGKALKAALKIGANALGGSPQQ
(8) GFASFLGKALKAALKIGANLLGGTPQQ
The above is expressed as single letter code for amino acids.
A review of the CPF peptides can be found in Richter K. Egger, R., and Kreil (1986) J. Biol. Chem 261, 3676-3680; Wakabayashi, T., Kato, H., and Tachibaba, S. (1985) Nucleic Acids Research 13, 1817-1828;
Gibson, B.W., Poulter, L., Williams, D.H., and
Maggio, J.E. (1986) J. Biol. Chem 261, 5341-5349.
It should be noted that no function has been ascribed to these peptides in- prior published
reports. Indeed, Kreil et al state in a recent paper: "At present it is not known whether these peptides have any biological activity." (Vlasak, R., Wiborg, O., Richter, K., Burgschwaiger, J.V., and Kreil, G., (1987) Eur. J. Bichem. 169, p. 53).
In accordance with one aspect of the present invention, there is provided a composition comprised of CPF peptides and/or biologically active analogues or derivatives thereof and a pharmaceutical carrier.
In accordance with another aspect of the present invention, there is provided a process wherein a CPF peptide and/or biologically active analogue or derivative thereof is administered to inhibit growth of a target cell or cells.
The terms analogue and/or derivative encompasses peptides having more or less amino acids than the CPF peptides and one or more changes in the amino acids of the CPF peptide.
CPF peptides as well as analogues and
derivatives thereof are herein sometimes referred to collectively as CPF peptides.
The CPF peptide is preferably one which includes the following basic peptide structure x:
-R1-R1-R2-R2-R1-R1-R3-R1- -R1-R1-R3-R1-R1-R4-R5-R1- wherein R1 is a hydrophσbic amino acid;
R2 is a hydrophobic amino acid or a basic hydrophilic amino acid;
R3 is a basic hydrophilic amino acid;
R4 is a hydrσphobic or neutral hydrophilic amino acid; and
R5 is a basic or neutral hydrophilic amino acid.
The hereinabove basic structure is hereinafter symbolically indicated as X.
The hydrophobic amino acids are Ala, Cys, Phe, Gly, lie, Leu, Met, Val, Trp, and Tyr.
The neutral hydrophilic amino acids are Asn, Gin, Ser, and Thr.
The basic hydrophilic amino acids are Lys, Arg, and His.
The CPF peptide may include only the hereinabove noted amino acids or may include additional amino acids at the amino and/or carboxyl end or both the amino and carboxyl end. In general, the peptide does not include more than 40 amino acids.
The CPF peptides including the above basic structure preferably have from 1 to 4 additional amino acids at the amino end.
Accordingly, such preferred peptides may be represented by the structural formula:
Y - X - wherein X is the hereinabove described basic peptide structure and Y is
(i) R5-, or
(ii) R2-R5-; or
(iii) R,-R2-R5; or
(iv) R2-R1-R2-R5; Preferat,ly
Glycine - R1-R2-R5.
wherein R1, R2 and R5 are as previously defined.
The carboxyl end of the basic peptide structure may also have additional amino acids which may range from 1 to 13 additional amino acids.
In a preferred embodiment, the basic structure may have from 1 to 7 additional amino acids at the carboxyl end, which may be represented as follows:
-X - Z wherein
X is the hereinabove defined basic peptide structure and Z is
(i) R1-, or
(ii) R1-R1 ; or
(iii) R1-R1-R4; or
(iv) R1-R1-R4-R4; or
(v) R1-R1-R4-R4-R6; or
(vi) R1-R1-R4-R4-R6-Gln; or
(vii) R1-R1-R4-R4-R6-Gln-Gln, wherein R1 and R4 are as previously defined, and R6 is proline or a hydrophobic amino acid.
Preferred peptides may be represented by the following structural formula
(Z)a - X - (Z)b wherein X, Y and Z are as previously defined and a is 0 or 1 and b is 0 or 1.
As representative examples of CPF like peptides used in the present invention, there may be mentioned peptides represented by the following (single letter amino acid code):
G12S3LG4ALKA5LKIG678LGG9(10)QQ
Where :
1 = F, L
2 = G, A
3 = F, L
4 = K, L
5 = A, G, T
6 = A, T
7 = H , N
8 = A , M , F , L
9 = A , S , T
10 = P , L
The numbered amino acids may be employed as described in any combination to provide either a basic CPF peptide structure or an analogue or
derivative thereof.
The CPF peptides and/or analogues and/or
derivatives thereof are ion channel forming peptides. An ion channel forming peptide or ionophore is one which increases the permeability for ions across a natural or synthetic lipid membrane. Christensen et al. PNAS Vol. 85 P. 5072-76 (July 1988) describes methodology which indicates whether or not a peptide has ion channel properties and is therefore an ionophore. A used herein an ion channel- forming peptide is a peptide which has ion channel-forming properties as determined by the method of
Christensen, et al.
In general, the CPF peptides and/or analgoues or derivatives thereof are generally water soluble to a concentration of at least 20 mg/ml at neutral pH in water. In addition, such peptides are non-hemolytic; i.e., they will not rupture blood cells at effective concentrations. In addition, the structure of such peptide provides for flexibility of the peptide molecule. When the peptide is placed in water, it does not assume an amphiphilic structure. When the peptide encounters an oily surface or membrane, the peptide chain folds upon itself into a rod-like structure.
The CPF peptides and/or analogues or derivatives thereof may be administered to a host; for example a human or non-human animal, in an amount effective to inhibit growth of a target cell. Thus, for example, the CPF peptides and/or analogues or derivatives thereof may be used as antimicrobial agents
anti-viral agents, antibiotics, anti-tumor agents, spermicides, as well as exhibiting other bioactive functions.
The term "antimicrobial" as used herein means that the polypeptides of in the present invention inhibit, prevent, or destroy the growth or
proliferation of microbes such as bacteria, fungi, viruses, or the like.
The term "antibiotic" as used herein means that the polypeptides employed in the present invention produce effects adverse to the normal biological functions of the cell, tissue, or organism including death or destruction and prevention of the growth or proliferation of the biological system when contacted with the polypeptides.
The term "spermicidal" as used herein means that the polypeptides employed in the present invention, inhibit, prevent, or destroy the motility of sperm.
The term "antiviral" as used herein means that the polypeptides employed in the present invention inhibit, prevent, or destroy the growth or
proliferation of viruses.
The term anti-tumor as used herein means that the polypeptide inhibits the growth of or destroys tumors.
The polypeptides of the present invention have a broad range of potent antibiotic activity against a
plurality of microorganisms including gram-positive and gram-negative bacteria, fungi, protozoa, and the like. The polypeptides of the present invention allow a method for treating or controlling microbial infection caused by organisms which are sensitive to the polypeptides. Such treatment may comprise administering to a host organism or tissue
susceptible to or affiliated with a microbial
infection an antimicrobial amount of at least one of the polypeptides.
Because of the antibiotic properties of the polypeptides, they may also be used as preservatives or sterilants of materials susceptible to microbial contamination.
The CPF peptide and/or derivatives or analogues thereof may be administered in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution. Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule, or the like. The polypeptide compositions may also be used in combination with adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in controlling infection caused by harmful
microorganisms including protozoa viruses, and the like.
The peρtide(s) of the present invention may be administered to a host; in particular an animal, in an effective antibiotic and/or anti-tumor and/or
anti-viral and/or anti-microbial and/or an
antispermicidal amount.
Depending on the use, a composition in
accordance with the invention will contain an
effective anti-microbial amount and/or an effective antispermicidal amount and/or an effective anti-viral amount and/or an effective anti-tumor amount and/or an effective anti-biotic amount of one or more of the hereinabove described peptides which have such activity.
The peptides, when used in topical compositions, are generally present in an amount of at least 0.1%, by weight. In most cases, it is not necessary to employ the peptide in an amount greater than 1.0%, by weight.
In employing such compositions systemically (intramuscular, intravenous, intraperitoneal), the active peptide is present in an amount to achieve a serum level of the peptide of at least about 5 ug/ml. In general, the serum level of peptide need not exceed 500 ug/ml. A preferred serum level is about 100 ug/ml. Such serum levels may be achieved by incorporating the peptide in a composition to be administered systemically at a dose of from 1 to about 10 mg/kg. In general, the ρeptide(s) need not be administered at a dose exceeding 100 mg/kg.
The present invention will be further described with respect to the following examples; however, the scope of the invention is not to be limited thereby:
TABLE I demonstrates the antibacterial activity of the peptide GFGSFLGLALKAALKIGANALGGAPQQ [CPF (I)] and the peptide GFASFLGKALKAALKIGANLLGGTPQQ [CPF
(II)].
TABLE II shows the minimal inhibitory concentrations of CPF (I) and CPF (II) against several strains of bacteria and fungi.
TABLE III lists the minimal effective concentrations of CPF (I) and CPF (II) necessary to physically disrupt several different species of protozoa. In each case the peptide induces osmotic swelling.
TABLE III SENSITIVITY OF PROTOZOA TO SYNTHETIC PEPTIDES
(Legend) Cells were grown in MEM with 10% fetal calf serum. Peptide was added directly to a well
containing a confluent lawn of cells and incubated at 37ºC for 30 min. The concentration at which greater than 90% of the cells were killed as determined by permeabilization to Trypan Blue is noted.
Numerous modifications and variations of the present invention are possible in light of the above teachings; therefore, within the scope of the
appended claims the invention may be practiced otherwise than as particularly described.
Claims
1. A composition, comprising:
at least one peptide which is a CPF peptide or biologically active analogue or derivative thereof and a pharmaceutical carrier.
2. The composition of Claim 1 wherein the peptide includes the following basic structure X:
-R1-R1-R2-R2-R1-R1-R3-R1-
-R1-R1-R3 -R1-R1-R4-R5-R1
wherein R1 is a hydrophobic amino acid; R2 is a basic hydrophilic amino acid or a hydrophobic amino acid, R3 is a basic hydrophilic amino acid, R4 is a hydrophobic or neutral hydrophilic amino acid, and R5 is a basic or neutral hydrophilic amino acid.
3. The composition of Claim 2 wherein the peptide includes the following structure
Y - X - wherein X is the basic peptide structure of Claim 2
and Y is R5-; R2-R5-; R1-R2-R5- or R2-R1-R2-R5.
4. The composition of Claim 2 wherein the peptide includes the following basic structure
- X - Z- wherein X is the basic peptide structure of Claim 2 and Z is:
R1 ; R1-R1; R1-R1-R4; R1-R1-R4-R4;
R1-R1-R4-R4-R6;
R1-R1-R4-R4-R6-Gln; or
R1-R1-R4-R4-R6-Gln-Gln, wherein
R6 is proline or a hydrophobic amino acid.
5. The composition of Claim 1 wherein the peptide includes the following basic structure.
(Y)a - X - (Z)b wherein Y and Z are as previously defined in Claims 3 and 4,
a is 0 or 1, and b is 0 or 1.
6. The composition of Claim 1 wherein said CPF peptide or biologically active analogue or derivative thereof is present in an amount effective to inhibit growth of a target cell.
7. The composition of Claim 1 wherein the peptide has the following structure:
G12S3LG4ALKA5LKIG678LGG9 (10)QQ
Where:
1 = F, L
2 = G, A
3 = F, L
4 = K, L
5 = A, G, T
6 = A, T
7 = H, N
8 = A, M, F, L
9 = A, S, T
10 = P, L
8. A process for inhibiting growth of a target cell, comprising:
administering at least one CPF peptide or analogue or derivative thereof in an amount effective to inhibit growth of a target cell.
9. The process of Claim 8 wherein said
administering is to an animal host in an effective anti-tumor amount.
10, The process of Claim 8 wherein said
administering is to an animal host in an effective anti-viral amount.
11. The process of Claim 8 wherein said
administering is to an animal host in an effective antimicrobial amount.
12. The process of Claim 8 wherein said
administering is to an animal host in an effective antibiotic amount.
13. The process of Claim 8 wherein said
administering is to an animal host in an effective anti-spermicidal amount.
14. The process of Claim 8 wherein the peptide includes the following basic structure X
-R1-R1-R2-R2-R1-R1-R3-Rl-
-R1-R1-R3-R1-R1-R4-R5-Rl
wherein R1 is a hydrophobic amino acid; R2 is a basic hydrophilic amino acid or a hydrophobic amino acid, R3 is a basic hydrophilic amino acid, R4 is a hydrophobic or neutral hydrophilic amino acid, and R5 is a basic or neutral hydrophilic amino acid.
15. The process of Claim 14 wherein the peptide includes the following structure
Y - X - wherein X is the basic peptide structure of Claim 14
and Y is R5-; R2-R5-; R1-R2-R5- or R2-R1-R2-R5.
16. The process of Claim 14 wherein the peptide includes the following basic structure
- X - Z- wherein X is the basic peptide structure of Claim 14 and Z is:
R1 ; R1-R1 ; R1-R1-R4 ; R1-R1-R4-R4 ;
R1-R1-R4-R4-R6 ;
R1-R1-R4-R4-R6-Gln; or R1-R1-R4-R4-R6-Gln-Gln, wherein R6 is proline or a hydrophobic amino acid.
17. The process of Claim 8 wherein the peptide includes the following basic structure.
(Y)a - X - (Z)b
wherein Y and Z are as previously defined, a is 0 or 1 and b is 0 or 1.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE68918453T DE68918453T2 (en) | 1988-10-21 | 1989-10-16 | Compositions based on CPF peptides and their uses. |
EP89911721A EP0440688B1 (en) | 1988-10-21 | 1989-10-16 | Cpf peptide compositions and uses |
KR1019900701329A KR900701299A (en) | 1988-10-21 | 1990-06-21 | CPF peptide composition and method of using the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26086188A | 1988-10-21 | 1988-10-21 | |
US260,861 | 1988-10-21 | ||
US36268989A | 1989-06-07 | 1989-06-07 | |
US362,689 | 1994-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990004407A1 true WO1990004407A1 (en) | 1990-05-03 |
Family
ID=26948228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/004625 WO1990004407A1 (en) | 1988-10-21 | 1989-10-16 | Cpf peptide compositions and uses |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0440688B1 (en) |
JP (1) | JPH04502901A (en) |
KR (1) | KR900701299A (en) |
CN (1) | CN1043874A (en) |
AT (1) | ATE111742T1 (en) |
AU (1) | AU4410989A (en) |
CA (1) | CA2001008A1 (en) |
DE (1) | DE68918453T2 (en) |
IL (1) | IL92030A (en) |
WO (1) | WO1990004407A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
EP0579763A1 (en) * | 1991-04-08 | 1994-01-26 | Magainin Pharmaceuticals Inc. | Novel peptide compositions and uses therefor |
WO1996022999A1 (en) * | 1995-01-24 | 1996-08-01 | Brian John Boughton | Peptides which inhibit viruses |
US5593866A (en) * | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
US6191254B1 (en) | 1995-08-23 | 2001-02-20 | University Of British Columbia | Antimicrobial cationic peptides |
US6297215B1 (en) | 1995-06-02 | 2001-10-02 | The University Of British Columbia | Antimicrobial cationic peptides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507230A (en) * | 1982-05-12 | 1985-03-26 | Research Corporation | Peptide synthesis reagents and method of use |
-
1989
- 1989-10-16 WO PCT/US1989/004625 patent/WO1990004407A1/en active IP Right Grant
- 1989-10-16 AT AT89911721T patent/ATE111742T1/en not_active IP Right Cessation
- 1989-10-16 AU AU44109/89A patent/AU4410989A/en not_active Abandoned
- 1989-10-16 JP JP1510942A patent/JPH04502901A/en active Pending
- 1989-10-16 EP EP89911721A patent/EP0440688B1/en not_active Expired - Lifetime
- 1989-10-16 DE DE68918453T patent/DE68918453T2/en not_active Expired - Fee Related
- 1989-10-17 IL IL9203089A patent/IL92030A/en not_active IP Right Cessation
- 1989-10-19 CA CA002001008A patent/CA2001008A1/en not_active Abandoned
- 1989-10-21 CN CN89108590A patent/CN1043874A/en active Pending
-
1990
- 1990-06-21 KR KR1019900701329A patent/KR900701299A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507230A (en) * | 1982-05-12 | 1985-03-26 | Research Corporation | Peptide synthesis reagents and method of use |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
EP0579763A1 (en) * | 1991-04-08 | 1994-01-26 | Magainin Pharmaceuticals Inc. | Novel peptide compositions and uses therefor |
EP0579763A4 (en) * | 1991-04-08 | 1994-12-21 | Magainin Pharma | Novel peptide compositions and uses therefor. |
US5593866A (en) * | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
WO1996022999A1 (en) * | 1995-01-24 | 1996-08-01 | Brian John Boughton | Peptides which inhibit viruses |
US6297215B1 (en) | 1995-06-02 | 2001-10-02 | The University Of British Columbia | Antimicrobial cationic peptides |
US6465429B1 (en) | 1995-06-02 | 2002-10-15 | The University Of British Columbia | Antimicrobial cationic peptides |
US6906035B2 (en) | 1995-06-02 | 2005-06-14 | The University Of British Columbia | Antimicrobial cationic peptides |
US6191254B1 (en) | 1995-08-23 | 2001-02-20 | University Of British Columbia | Antimicrobial cationic peptides |
US7390873B2 (en) | 1995-08-23 | 2008-06-24 | University Of British Columbia | Antimicrobial cationic peptides |
Also Published As
Publication number | Publication date |
---|---|
EP0440688B1 (en) | 1994-09-21 |
KR900701299A (en) | 1990-12-01 |
ATE111742T1 (en) | 1994-10-15 |
CN1043874A (en) | 1990-07-18 |
JPH04502901A (en) | 1992-05-28 |
EP0440688A1 (en) | 1991-08-14 |
EP0440688A4 (en) | 1992-07-08 |
CA2001008A1 (en) | 1990-04-21 |
IL92030A (en) | 1994-05-30 |
DE68918453T2 (en) | 1995-02-23 |
AU4410989A (en) | 1990-05-14 |
DE68918453D1 (en) | 1994-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5221664A (en) | Composition and treatment with biologically active peptides and toxic cations | |
US5073542A (en) | CPF peptide compositions and their use in inhibiting growth of target cells or a virus | |
EP0667871A1 (en) | Biologically active amphiphilic peptide compositions and uses therefor | |
US5424290A (en) | Biologically active peptides and uses therefor | |
KR101700603B1 (en) | An anti-microbial peptide, Periplanetasin-1 isolated from Periplaneta americana and its synthetic composition | |
CA2086111A1 (en) | Biologically active peptide compositions and uses therefor | |
US5225399A (en) | Antimicrobial amphiphilic peptides | |
US5620954A (en) | Peptide compositions and uses therefor | |
US5235038A (en) | Deletion and substitution analogues of melittin peptide | |
US5217956A (en) | Composition and treatment with biologically active peptides and certain anions | |
US5114921A (en) | Amphiphilic peptides and use thereof | |
US5208220A (en) | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase | |
EP0440688B1 (en) | Cpf peptide compositions and uses | |
WO1989011290A1 (en) | Amphiphilic peptides and use thereof | |
KR20170053877A (en) | An anti-microbial peptide, Oxyasin-2 isolated from Oxya chinensis sinuosa and its synthetic composition | |
AU641129B2 (en) | Composition and treatment with biologically active peptides and certain anions | |
WO1991016066A1 (en) | Composition and treatment with biologically active peptides and toxic cations | |
US5254537A (en) | Composition and treatment with peptide combinations | |
EP0455719A4 (en) | Composition and treatment with peptide combinations | |
WO1991017760A1 (en) | Composition of and treatment with biologically active peptides having d-amino acid residues | |
WO1991016918A1 (en) | Composition and treatment with biologically active peptides and anti-parasitic agents or anti-fungal agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR DK FI JP KR NO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1989911721 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1989911721 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1989911721 Country of ref document: EP |